# EDGAR Filing Document

**Accession Number:** 0001236371
**File Stem:** 0001193125-25-317968
**Filing Date:** 2025-12
**Character Count:** 8431
**Document Hash:** ee02cb00686de043f751aaafbaa7929c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-317968.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001193125-25-317968

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251212

**FILED AS OF DATE**: 20251212

**DATE AS OF CHANGE**: 20251212

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** PERRY GREGORY D
- **CENTRAL INDEX KEY:** 0001236371

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37773
- **FILM NUMBER:** 251569602

**MAIL ADDRESS:**
- **STREET 1:** C/O IMMUNOGEN, INC.
- **STREET 2:** 830 WINTER ST.
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merus N.V.
- **CENTRAL INDEX KEY:** 0001651311
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** 3584 CM UTRECHT
- **STATE:** DE
- **BUSINESS PHONE:** 31 030 253 8800

**MAIL ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** 3584 CM UTRECHT
- **STATE:** DE

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merus B.V.
- **DATE OF NAME CHANGE:** 20150819

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>PERRY GREGORY D<br><sub>(Last) (First) (Middle)</sub><br>C/O MERUS N.V.<br>UPPSALALAAN 17<br><sub>(Street)</sub><br>UTRECHT, P7 3584 CT<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-12-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer & PFO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Merus N.V. [ MRUS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Share Option (right to buy) | $41.65 | 2025-12-12 |  | D |  |  | 100000 | <sup>(1)(2)</sup> | 2035-01-29 | Common Shares | 100000 | $0 | 0 | D |  |
| Share Option (right to buy) | $36.09 | 2025-12-12 |  | D |  |  | 107300 | <sup>(1)(2)</sup> | 2034-01-31 | Common Shares | 107300 | $0 | 0 | D |  |
| Share Option (right to buy) | $26.50 | 2025-12-12 |  | D |  |  | 372924 | <sup>(1)(2)</sup> | 2033-06-14 | Common Shares | 372924 | $0 | 0 | D |  |
| Share Option (right to buy) | $23.29 | 2025-12-12 |  | D |  |  | 14414 | <sup>(1)(2)</sup> | 2033-06-08 | Common Shares | 14414 | $0 | 0 | D |  |
| Share Option (right to buy) | $18.56 | 2025-12-12 |  | D |  |  | 16604 | <sup>(1)(2)</sup> | 2032-05-31 | Common Shares | 16604 | $0 | 0 | D |  |
| Share Option (right to buy) | $21.15 | 2025-12-12 |  | D |  |  | 6120 | <sup>(1)(2)</sup> | 2031-05-28 | Common Shares | 6120 | $0 | 0 | D |  |
| Share Option (right to buy) | $16.09 | 2025-12-12 |  | D |  |  | 8631 | <sup>(1)(2)</sup> | 2030-06-30 | Common Shares | 8631 | $0 | 0 | D |  |
| Share Option (right to buy) | $10.04 | 2025-12-12 |  | D |  |  | 17000 | <sup>(1)(2)</sup> | 2026-05-18 | Common Shares | 17000 | $0 | 0 | D |  |
| Share Option (right to buy) | $19.12 | 2025-12-12 |  | D |  |  | 5650 | <sup>(1)(2)</sup> | 2027-05-24 | Common Shares | 5650 | $0 | 0 | D |  |
| Share Option (right to buy) | $23.30 | 2025-12-12 |  | D |  |  | 4983 | <sup>(1)(2)</sup> | 2028-07-20 | Common Shares | 4983 | $0 | 0 | D |  |
| Share Option (right to buy) | $13.35 | 2025-12-12 |  | D |  |  | 8500 | <sup>(1)(2)</sup> | 2029-06-12 | Common Shares | 8500 | $0 | 0 | D |  |

---

### Footnotes:

(1) On September 29, 2025, Merus N.V. (the "Issuer") entered into a transaction agreement (as it may be amended, supplemented or otherwise modified from time to time, the "Transaction Agreement") with Genmab A/S ("Genmab") and its wholly owned subsidiary, Genmab Holding II B.V. (the "Purchaser"). Pursuant to the terms of the Transaction Agreement, the Purchaser commenced a tender offer for all the issued and outstanding common shares, par value EUR 0.09 per share (the "Shares"), of the Issuer (the "Offer"), and, on December 12, 2025 (the "Acceptance Time"), the Purchaser accepted all of the Shares that were validly tendered and not properly withdrawn pursuant to the Offer as of the Acceptance Time in exchange for a cash payment equal to $97.00 per Share, without interest and less applicable withholding taxes (the "Offer Consideration"), which Offer Consideration will be paid as soon as practicable following the Acceptance Time.

(2) This option was cancelled pursuant to the Transaction Agreement in exchange for cash (without interest and net of applicable withholding tax and other applicable deductions) in an amount equal to the product of (i) the amount by which the Offer Consideration exceeds the applicable exercise price per Share of such option and (ii) the aggregate number of Shares underlying such option.

**Signature:** /s/ Peter Silverman as attorney-in-fact  
**Date:** 2025-12-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**